Welcome to our dedicated page for Zimmer Biomet news (Ticker: ZBH), a resource for investors and traders seeking the latest updates and insights on Zimmer Biomet stock.
Zimmer Biomet Holdings, Inc. reports developments across its global medical technology business, including orthopedic reconstructive implants, surgical products, and integrated digital and robotic technologies that use data, analytics and artificial intelligence. Company updates commonly cover quarterly results and guidance, dividend actions, health care conference appearances, executive leadership changes, and clinical or operational data presented at orthopedic meetings.
Product-focused announcements describe musculoskeletal care technologies such as Oxford Cementless Partial Knee, Persona OsseoTi Keel Tibia, and HAMMR Automated Hip Impaction System, alongside broader portfolio themes in knees, hips, smart implants, robotics, AI and medical education.
Zimmer Biomet Holdings, Inc. has appointed Vafa Jamali as the CEO of NewCo, a spin-off company which will focus on the Spine and Dental sectors, expected to launch in mid-2022. Jamali brings over 25 years of medical device experience, previously holding leadership roles at Rockley Photonics and Medtronic, where he led a $3 billion revenue division. His expertise is anticipated to drive growth and investment strategies for NewCo. Bryan Hanson, the current CEO of Zimmer Biomet, expressed confidence in Jamali’s ability to lead the new venture successfully.
Zimmer Biomet (ZBH) announced that President and CEO Bryan Hanson, along with Executive Vice President and CFO Suky Upadhyay, will present at Citi's 2021 Healthcare Services Conference on February 24, 2021, at 10:45 a.m. ET. A live webcast can be accessed via their Investor Relations website, which will also archive the presentation for later viewing. Zimmer Biomet, headquartered in Warsaw, Indiana, is a key player in musculoskeletal healthcare, offering a wide range of medical products and solutions.
Zimmer Biomet (NYSE: ZBH) plans to spin off its Spine and Dental businesses into a new independent company, NewCo, aiming to optimize growth and stakeholder value. This strategic move, part of Zimmer Biomet's transformation, focuses resources on higher-growth markets, including orthopedics and dental sectors. The spin-off, expected mid-2022, is designed to create stronger growth profiles for both companies while achieving a more targeted investment opportunity. The 2019 and 2020 pro forma revenue for Zimmer Biomet was $6.96 billion and $6.128 billion, respectively.
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) reported its Q4 2020 results, revealing net sales of $2.085 billion, down 1.9%, with full-year sales at $7.025 billion, a 12% decrease. Q4 net earnings reached $333.7 million, equating to diluted EPS of $1.59, a 3.2% increase year-over-year. Adjusted diluted EPS fell 8.3% to $2.11. The company announced plans to spin off its Spine and Dental divisions to enhance focus and growth. Despite strong operational performance, the ongoing impact of COVID-19 on elective procedures continues to hinder recovery.
Zimmer Biomet Holdings has appointed Ellison M. Humphrey as the Chief Transformation Officer, reporting directly to Bryan C. Hanson, President and CEO. Humphrey joins from Medtronic, where she held leadership roles including Vice President of Enterprise Excellence. In her new role, she will connect key initiatives to drive an integrated transformation strategy across the organization. Her extensive experience, including a background at McKinsey & Company and degrees from Harvard and the University of Virginia, is expected to advance Zimmer Biomet’s goals within the evolving healthcare landscape.
Zimmer Biomet Holdings (ZBH) will host a fourth quarter earnings conference call on February 5, 2021, at 8:30 a.m. ET, following a news release of financial results at 6:30 a.m. ET the same day. The conference call will be accessible via their Investor Relations website and will be archived for replay. U.S. and Canadian participants can join by calling (888) 312-9837 using conference ID 7278985. The digital recording will be available until April 6, 2021.
Zimmer Biomet Holdings (ZBH) has announced a $0.24 quarterly cash dividend for Q4 2020. This dividend will be paid on or about January 29, 2021 to stockholders on record as of the close of business on December 28, 2020. Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a leader in musculoskeletal healthcare, providing various orthopedic products worldwide.
Zimmer Biomet Holdings (NYSE: ZBH) announced its participation in the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 3:40 p.m. ET. Presenters include President and CEO Bryan Hanson and Executive Vice President and CFO Suky Upadhyay. A live webcast will be available on Zimmer Biomet's Investor Relations website and archived for future viewing. Zimmer Biomet is a leader in musculoskeletal healthcare, designing and marketing a wide range of orthopedic and surgical products globally.
Zimmer Biomet Holdings and Hospital for Special Surgery (HSS) have announced an exclusive agreement to implement HSS Orthopedic Care Pathways via the mymobility platform with Apple Watch. This collaboration aims to enhance remote patient care through state-of-the-art surgical care protocols. By utilizing Apple Watch's sensors, physicians can monitor patients' activity and recovery metrics, facilitating virtual doctor-patient interactions and potentially lowering care costs. The new pathways will be available globally in early 2021.
Zimmer Biomet Holdings (NYSE: ZBH) has launched the Zimmer Biomet Foundation, a philanthropic organization aimed at supporting diverse and underserved communities. The Foundation will focus on STEM education, community health, and disaster relief. Zimmer Biomet pledges $2 million over three years in partnership with the NAACP to combat racial injustice and promote diversity. This initiative is part of a larger commitment of at least $5 million over five years towards anti-racism and diversity efforts. The Foundation will also match employee contributions to non-profits.